US healthcare company GRAIL Inc (Nasdaq:GRAL) announced on Monday that the patient-reported outcomes (PRO) evaluating patient perspectives from the PATHFINDER study of its Galleri multi-cancer early detection blood test have been published in Lancet Oncology.
The study included secondary and exploratory outcomes with the objective of assessing PRO and perceptions of multi-cancer early detection (MCED) testing.
PRO assessment was conducted for eligible PATHFINDER study participants with either a cancer signal detected (CSD) or no cancer signal detected (NCSD) over a 12-month follow-up period. General anxiety, distress and uncertainty after results disclosure, health-related quality of life, satisfaction with the Galleri test, and intent towards guideline-recommended screening and repeat MCED testing were assessed.
Overall, the study demonstrated minimal patient distress associated with MCED testing. Most participants with a NCSD result responded that they were "relieved about my test result".
Lincoln Nadauld, MD, lead author of the study and vice president, chief of Precision Health & Academics at Intermountain Health during the PATHFINDER study and currently CEO at Culmination Bio Inc, said: "Previous studies have shown that there is a temporary increase in anxiety symptoms after cancer screening, particularly for those with a test result indicating they may have cancer. PRO results in the PATHFINDER study were consistent with other studies and showed the transient nature of the anxiety increase coupled with satisfaction with the screening and commitment to continue their standard screenings along with MCED testing. These encouraging results indicate that MCED could be a valuable tool for early detection with minimal distress for patients."
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
CHMP recommends EU approval of Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan
Invenra and Orion partner to develop bispecific antibody cancer therapies
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
ImmunityBio partners with BeiGene for Phase 3 NSCLC trial of ANKTIVA and PD-1 inhibitor
Diatech Pharmacogenetics expands Merck collaboration for colorectal cancer testing